<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.0" xml:lang="hr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-147-57</article-id>
<article-id pub-id-type="doi">10.26800/LV-147-1-2-6</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group>
</article-categories>
<title-group>
<article-title>Biomarkeri u jedinici intenzivne medicine</article-title>
<trans-title-group xml:lang="en">
<trans-title>Biomarkers in the intensive care unit</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4521-4366</contrib-id><name><surname>Ostovi&#x0107;</surname><given-names>Helena</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>&#x0160;imac</surname><given-names>Brankica</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Per&#x0161;ec</surname><given-names>Jasminka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib>
<aff id="aff1"><label>1</label><institution>Klinika za anesteziologiju, reanimatologiju i intenzivnu medicinu, Klini&#x010D;ka bolnica Dubrava</institution>, <addr-line>Zagreb</addr-line></aff>
<aff id="aff2"><label>2</label><institution>Medicinski fakultet Osijek, Sveu&#x010D;ili&#x0161;te J. J. Strossmayera u Osijeku</institution>, <addr-line>Osijek</addr-line></aff>
<aff id="aff3"><label>3</label><institution>Klini&#x010D;ki zavod za laboratorijsku dijagnostiku, Klini&#x010D;ka bolnica Dubrava</institution>, <addr-line>Zagreb</addr-line></aff>
<aff id="aff4"><label>4</label><institution>Stomatolo&#x0161;ki fakultet, Sveu&#x010D;ili&#x0161;te u Zagrebu</institution>, <addr-line>Zagreb</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Adresa za dopisivanje: Helena Ostovi&#x0107;, dr. med., <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-4521-4366">https://orcid.org/0000-0002-4521-4366</ext-link>, Klinika za anesteziologiju, reanimatologiju i intenzivnu medicinu, Klini&#x010D;ka bolnica Dubrava, Avenija Gojka &#x0160;u&#x0161;ka 6, 10000 Zagreb, e-po&#x0161;ta: <email xlink:href="helenaostovic@gmail.com">helenaostovic@gmail.com</email></corresp>
<fn id="afn1"><p>Ustanova u kojoj je rad napravljen:</p></fn>
<fn id="afn2"><p>Klinika za anesteziologiju, reanimatologiju i intenzivnu medicinu, Klini&#x010D;ka bolnica Dubrava, Zagreb, Avenija Gojka &#x0160;u&#x0161;ka 6, 10000 Zagreb</p></fn>
<fn fn-type="con">
<p content-type="fn-title">DOPRINOS AUTORA</p>
<p>K<sc>oncepcija</sc> <sc>ili</sc> <sc>nacrt</sc> <sc>rada</sc>: HO, JP</p>
<p>P<sc>rikupljanje</sc>, <sc>analiza</sc> <sc>i</sc> <sc>interpretacija</sc> <sc>podataka</sc>: HO, B&#x0160;</p>
<p>P<sc>isanje</sc> <sc>prve</sc> <sc>verzije</sc> <sc>rada</sc>: HO, B&#x0160;</p>
<p>K<sc>riti&#x010D;ka</sc> <sc>revizija</sc>: JP</p>
</fn>
</author-notes>
<pub-date date-type="pub" publication-format="electronic"><month>03</month><year>2025</year></pub-date>
<pub-date date-type="pub" publication-format="print"><month>03</month><year>2025</year></pub-date>
<volume>147</volume>
<issue>1-2</issue>
<fpage>57</fpage>
<lpage>65</lpage>
<permissions>
<copyright-statement>Croatian Medical Association</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<p>Biomarkeri su pokazatelji &#x010D;ije se koncentracije u biolo&#x0161;kom uzorku mogu objektivno mjeriti i &#x010D;ije se razine koriste kao indikatori normalnog ili patolo&#x0161;kog procesa u organizmu, kao i odgovora na primijenjenu terapiju. Imaju rastu&#x0107;u popularnost u jedinicama intenzivne medicine (JIM) kao alat za dijagnostiku i pra&#x0107;enje razli&#x010D;itih bolesti. Od posebnog zna&#x010D;enja su biomarkeri upale koji poma&#x017E;u klini&#x010D;arima u razlu&#x010D;ivanju infektivne od neinfektivne etiologije upalnih stanja, koja su &#x010D;est problem kod bolesnika u JIM-u. Rano prepoznavanje infekcije i pravovremeno postavljanje dijagnoze sepse klju&#x010D;an su preduvjet lije&#x010D;enja kojemu je primarni cilj &#x0161;to ranije zapo&#x010D;injanje s odgovaraju&#x0107;om antimikrobnom terapijom. Unato&#x010D; rapidnom pove&#x0107;anju novootkrivenih biljega upale posljednjih godina, u klini&#x010D;koj praksi koristi ih se svega nekoliko i niti jedan nije idealan zbog grani&#x010D;ne osjetljivosti i nedostatne specifi&#x010D;nosti. Ovaj &#x010D;lanak daje pregled rutinski kori&#x0161;tenih biomarkera upale u JIM-u, ali daje i prikaz predstavnika nove generacije &#x010D;ija je namjena prvenstveno rano otkrivanje sepse. Biomarkerima upale, u klasi&#x010D;nom smislu, smatraju se broj leukocita, feritin, C-reaktivni protein (CRP), interleukin 6 (IL-6) i prokalcitonin (PCT), dok su &#x0161;irina distribucije monocita (MDW), presepsin i protein pankreasnog kamenca (PSP) relativno novijeg datuma. Kombinacija novih i tradicionalnih biomarkera upale kao ranih odnosno potvrdnih indikatora te njihova interpretacija u sklopu klini&#x010D;kih pokazatelja &#x010D;ine temelj personaliziranog pristupa svakom kriti&#x010D;no oboljelom bolesniku. Iako istra&#x017E;ivanja na ovom podru&#x010D;ju bilje&#x017E;e kontinuirani napredak uz obe&#x0107;avaju&#x0107;e rezultate, jo&#x0161; uvijek ne postoji samostalni biomarker koji je validiran za definitivnu dijagnozu sepse.</p>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<p>Biomarkers are indicators whose concentrations in a biological sample can be objectively measured, and their levels are used as indicators of a normal or pathological process in the body, as well as the response to applied therapy. They are gaining increasing popularity in intensive care units (ICUs) as a tool for diagnosing and monitoring various diseases. Inflammatory biomarkers are of special significance as they help clinicians differentiate between infectious and non-infectious etiologies of inflammatory conditions, which are common problems in ICU patients. Early detection of infections and timely diagnosis of sepsis are crucial prerequisites for treatment, with the primary goal to start appropriate antimicrobial therapy as early as possible. Despite the rapid increase in newly discovered inflammatory markers in recent years, only a few are used in clinical practice, and none are ideal due to borderline sensitivity and insufficient specificity. This article provides an overview of routinely used inflammatory biomarkers in ICUs and introduces representatives of the new generation, primarily intended for the early detection of sepsis. Classical inflammatory biomarkers include white blood cell count, ferritin, C-reactive protein (CRP), interleukin 6 (IL-6) and procalcitonin (PCT), while monocyte distribution width (MDW), presepsin, and pancreatic stone protein (PSP) are relatively new. The combination of new and traditional inflammatory biomarkers, as early or confirmatory indicators, and their interpretation in the context of clinical signs, forms the basis of a personalized approach to each critically ill patient. Although research in this field is continuously advancing with promising results, there is still no standalone biomarker validated for the definitive diagnosis of sepsis.</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori BIOMARKERI &#x2013; u krvi</kwd><kwd>SEPSA &#x2013; dijagnoza</kwd><kwd>JEDINICE INTENZIVNOG LIJE&#x010C;ENJA</kwd><kwd>BROJ LEUKOCITA &#x2013; analiza</kwd><kwd>C-REAKTIVNI PROTEIN &#x2013; u krvi</kwd><kwd>INTERLEUKIN-6 &#x2013; u krvi</kwd><kwd>PROTEIN PANKREASNOG KAMENCA &#x2013; u krvi</kwd><kwd>PROKALCITONIN &#x2013; u krvi</kwd><kwd>PEPTIDNI FRAGMENTI &#x2013; u krvi</kwd><kwd>LIPOPOLISAHARIDNI RECEPTORI &#x2013; u krvi</kwd><kwd>MONOCITI</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>BIOMARKERS &#x2013; blood</kwd><kwd>SEPSIS &#x2013; diagnosis</kwd><kwd>INTENSIVE CARE UNITS</kwd><kwd>LEUKOCYTE COUNT &#x2013; analysis</kwd><kwd>C-REACTIVE PROTEIN &#x2013; blood</kwd><kwd>INTERLEUKIN-6 &#x2013; blood</kwd><kwd>LITHOSTATHINE &#x2013; blood</kwd><kwd>PROCALCITONIN &#x2013; blood</kwd><kwd>PEPTIDE FRAGMENTS &#x2013;blood</kwd><kwd>LIPOPOLYSACCHARIDE RECEPTORS &#x2013; blood</kwd><kwd>MONOCYTES</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Kori&#x0161;tenje biomarkera ima rastu&#x0107;u popularnost u jedinicama intenzivne medicine (JIM) kao alat za dijagnostiku i pra&#x0107;enje velikog broja klini&#x010D;kih stanja. Pod terminom &#x201E;biomarker&#x201C; op&#x0107;enito se podrazumijeva bilo koji pokazatelj &#x010D;ija se koncentracija u biolo&#x0161;kom uzorku mo&#x017E;e objektivno mjeriti i &#x010D;ije se razine koriste kao indikator normalnog ili patolo&#x0161;kog procesa u organizmu, kao i odgovora na primijenjenu terapiju. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) Budu&#x0107;i da imaju vrlo &#x0161;iroko podru&#x010D;je primjene, radna skupina pri Ameri&#x010D;koj agenciji za hranu i lijekove (engl. <italic>U.S. Food and Drug Administration</italic>, FDA) i Nacionalnih instituta za zdravlje (engl. <italic>National Institutes of Health</italic>, NIH) klasificirala ih je u sedam kategorija: dijagnosti&#x010D;ki, prognosti&#x010D;ki, prediktivni, zatim biomarkeri rizika, pra&#x0107;enja (monitoringa), odgovora i sigurnosti. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Ovdje &#x0107;emo opisati one kojima se svakodnevno bavimo u kontekstu dijagnostike, procjene i kontrole upalnih procesa.</p>
<p>Upalna stanja, bilo zbog infektivne ili neinfektivne etiologije uslijed razli&#x010D;itih kriti&#x010D;nih bolesti, traume i poslijeoperacijskoga upalnog odgovora, &#x010D;est su problem kod bolesnika u JIM-u. Procjenjuje se da u&#x010D;estalost infekcija u JIM-u iznosi od 18% do 54% sa stopom smrtnosti koja se kre&#x0107;e izme&#x0111;u 9% i 60%. (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) S obzirom na to da je rije&#x010D; o stanju s visokim morbiditetom i mortalitetom, razlu&#x010D;ivanje infekcije od ostalih heterogenih uzroka upale klju&#x010D;an je preduvjet lije&#x010D;enja kojemu je primarni cilj &#x0161;to ranije zapo&#x010D;injanje s odgovaraju&#x0107;om antimikrobnom terapijom. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>)</p>
<p>Uobi&#x010D;ajeni pristup evaluaciji infekcije temelji se na klini&#x010D;kim simptomima (povi&#x0161;ena tjelesna temperatura, tahikardija, tahipneja), pra&#x0107;enju vrijednosti biomarkera upale i podatcima dobivenim mikrobiolo&#x0161;kom analizom ciljanih uzoraka. Broj novootkrivenih biljega upale posljednjih se godina rapidno pove&#x0107;ao te je do danas poznato preko 250 prognosti&#x010D;ko-prediktivnih biomarkera za infekciju i sepsu. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) U klini&#x010D;koj praksi koristi ih se svega nekoliko i niti jedan nije idealan zbog grani&#x010D;ne osjetljivosti i nedostatne specifi&#x010D;nosti. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>, <xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) Upalnim biomarkerima, u klasi&#x010D;nom smislu, smatraju se broj leukocita, feritin, C-reaktivni protein (CRP), interleukin 6 (IL-6) i prokalcitonin (engl. <italic>procalcitonin,</italic> PCT), dok su &#x0161;irina distribucije monocita (engl. <italic>monocyte distribution width,</italic> MDW), presepsin i protein pankreasnog kamenca (engl. <italic>pancreatic stone protein,</italic> PSP) relativno novijeg datuma. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r2"><italic>2</italic></xref>, <xref ref-type="bibr" rid="r8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="r9"><italic>9</italic></xref>)</p>
<sec sec-type="other1">
<title>Broj leukocita</title>
<p>Broj leukocita s diferencijalnom krvnom slikom rutinski je kori&#x0161;ten i dugo etabliran biomarker sustavnoga upalnog odgovora. Pored odre&#x0111;ivanja ukupnog broja leukocita, analiza diferencijalne krvne slike daje informaciju o apsolutnom i relativnom broju pojedinih subpopulacija leukocita (neutrofili, limfociti, monociti, bazofili i eozinofili). Pozitivne strane ovoga laboratorijskog testa jesu &#x0161;iroka dostupnost, jednostavnost primjene, niska cijena pretrage i dobivanje rezultata u vrlo kratkom vremenskom roku zajedno s mogu&#x0107;no&#x0161;&#x0107;u ekstrakcije vrijednih informacija. Nedostatci su mu ograni&#x010D;ena analiti&#x010D;ka osjetljivost i specifi&#x010D;nost. Prilikom interpretacije ovoga hematolo&#x0161;kog parametra, pozornost treba usmjeriti na tri klju&#x010D;na elementa: oscilacije u broju leukocita, pomak ulijevo i neutrofilno/limfocitni omjer (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p>
<fig id="f1" position="float" fig-type="figure"><label>Figure 1</label><caption><p>Clinical interpretation of white blood cell count. The description of the figure is provided in the text.</p></caption><graphic xlink:href="LV-147-57-f1"></graphic></fig>
<p>Patolo&#x0161;ki broj leukocita mo&#x017E;e se manifestirati kao leukocitoza (&#x2265;12 &#x00D7; 10<sup>9</sup>/L) ili kao leukopenija (&#x2264;4 &#x00D7; 10<sup>9</sup>/L). (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) To je nespecifi&#x010D;an nalaz koji treba tuma&#x010D;iti u sklopu povijesti bolesti, fizikalnog pregleda, klini&#x010D;ke slike i ostale dijagnosti&#x010D;ke obrade. Leukocitoza se javlja tijekom infektivnih, ali i neinfektivnih zbivanja kao &#x0161;to su traumatska ozljeda tkiva, rano poslijeoperacijsko razdoblje i kriti&#x010D;ne bolesti razli&#x010D;ite etiologije. U odsutnosti jasnih klini&#x010D;kih znakova i simptoma, u dono&#x0161;enju terapijskih odluka mo&#x017E;e biti korisno poznavanje fiziolo&#x0161;ke dinamike promjena leukocita. U elektivnoj kirurgiji, vrijednosti leukocita po&#x010D;inju rasti neposredno nakon incizije, vr&#x0161;ne vrijednosti dosti&#x017E;u unutar 24 sata, a nakon 48 sati po&#x010D;inju opadati kod operacijskih zahvata nekompliciranog tijeka oporavka. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) Stoga, iako leukocitoza sugerira razvoj infekcije, nije potvrda iste, jer mo&#x017E;e biti i dio normalnoga upalnog odgovora kojim organizam nastoji oporaviti tkivni integritet i obnoviti homeostazu. Ako je laboratorijskim nalazom otkrivena leukopenija, tada je potrebno odrediti vrijednosti apsolutnog broja neutrofila (ukupnog broja zrelih ili tzv. segmentiranih neutrofila i njihovih nezrelih nesegmentiranih progenitora). Prisutnost te&#x0161;ke neutropenije s apsolutnim brojem neutrofila &lt;0,5 &#x00D7; 10<sup>9</sup>/L visoko je suspektna na postojanje infekcije.</p>
<p>Izrazom &#x201E;pomak ulijevo&#x201C; definira se pove&#x0107;anje omjera izme&#x0111;u nesegementiranih neutrofila i zrelih segmentiranih formi, dok se u klini&#x010D;kom okru&#x017E;enju koristi kao marker bakterijskih infekcija. (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>) Patofiziolo&#x0161;ku podlogu &#x010D;ini otpu&#x0161;tanje nezrelih oblika neutrofilnih granulocita iz ko&#x0161;tane sr&#x017E;i u perifernu krv kao posljedica njihove pove&#x0107;ane potro&#x0161;nje na mjestu infektivnog procesa i stimulacije proupalnim citokinima. U prvom redu u cirkulaciji se pojavljuju nesegmentirani neutrofili, a zatim ih slijede jo&#x0161; nezreliji oblici poput metamijelocita, mijelocita i promijelocita. (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) Obi&#x010D;no se prezentiraju 12 do 24 sata nakon nastanka bakterijske infekcije, a grani&#x010D;ne vrijednosti indikativne za dijagnozu uvelike se razlikuju prema podatcima iz dostupne literature. (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>) U skladu s ranije objavljenim studijama, ve&#x0107;inom se predla&#x017E;e definiranje pomaka ulijevo kada je udio nesegmentiranih neutrofila iznad 10 &#x2013; 20% ili kada je udio navedenih nezrelijih oblika iznad 0,2 &#x2013; 3% (niska osjetljivost, ali relativno visoka specifi&#x010D;nost). (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>, <xref ref-type="bibr" rid="r11"><italic>11</italic></xref>)</p>
<p>Neutrofilno/limfocitni omjer (engl. <italic>neutrophil to lymphocyte ratio,</italic> NLR) jest omjer izme&#x0111;u broja neutrofila (stani&#x010D;ne komponente priro&#x0111;ene imunosti) i broja limfocita (stani&#x010D;ne komponente ste&#x010D;ene imunosti). Rije&#x010D; je o visoko osjetljivom, ali nespecifi&#x010D;nom indikatoru sustavnoga upalnog odgovora i fiziolo&#x0161;kog stresa koji pouzdano reflektira te&#x017E;inu bolesti, ali ne poma&#x017E;e u diferencijalnoj dijagnozi konkretnog uzroka bolesti. (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) Pod utjecajem stresnog podra&#x017E;aja, vrlo vjerojatno zbog pove&#x0107;anja cirkuliraju&#x0107;ih razina endogenih katekolamina, kortizola, citokina i ostalih hormona u sklopu prate&#x0107;ih neuroendokrinih promjena, dolazi do istodobne neutrofilije i limfocitopenije, a samim time i povi&#x0161;enog NLR-a. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) Progresivni porast NLR-a nastupa vrlo rano, ve&#x0107; unutar prvih &#x0161;est sati nakon izlaganja stresoru, &#x0161;to ga &#x010D;ini superiornijim od nekih drugih parametara u smislu ranije identifikacije akutnog zbivanja (npr. ukupnog broja leukocita, skretanja ulijevo, CRP-a). (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>, <xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) Recentni pregledni rad definira normalne vrijednosti NLR-a u rasponu 1 &#x2013; 2, a vrijednosti iznad 3,0 i ispod 0,7 grani&#x010D;no patolo&#x0161;kim. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) U spomenutom radu autor nagla&#x0161;ava da rastu&#x0107;i trend NLR-a iznad navedenih referentnih granica pozitivno korelira s razinom stresa, intenzitetom upale i te&#x017E;inom same bolesti, dok se interval NLR-a izme&#x0111;u 2,3 i 3,0 ozna&#x010D;ava kao siva zona koja predstavlja upozoravaju&#x0107;i znak potencijalno patolo&#x0161;kog stanja u organizmu.</p>
</sec>
<sec sec-type="other2">
<title>Feritin</title>
<p>Feritin je proteinski kompleks sferi&#x010D;nog oblika koji se sastoji od proteinske ljuske sastavljene od 24 polipeptidne podjedinice sa &#x0161;upljim sredi&#x0161;tem koje mo&#x017E;e skladi&#x0161;titi do 4.500 atoma &#x017E;eljeza u netoksi&#x010D;nom obliku. (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>, <xref ref-type="bibr" rid="r15"><italic>15</italic></xref>) Prvi put je izoliran iz slezene konja 1937. godine kao protein sa sadr&#x017E;ajem &#x017E;eljeza ve&#x0107;im od 20%, a za njegovo otkri&#x0107;e zaslu&#x017E;an je &#x010D;e&#x0161;ki fiziolog Vil&#x00E9;m Laufberger (1890.&#x2005;&#x2013;&#x2005;1986.). (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>&#x2013;<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>) To je prvenstveno unutarstani&#x010D;ni protein s funkcijom pohrane &#x017E;eljeza koji je najve&#x0107;im dijelom akumuliran u stanicama jetre i retikuloendotelnim stanicama ko&#x0161;tane sr&#x017E;i i slezene. Glavnim izvorom feritina smatraju se hepatociti, makrofagi i Kupfferove stanice, a klju&#x010D;nu ulogu u regulaciji njegovih serumskih razina imaju neravnote&#x017E;a &#x017E;eljeza, hormoni i proupalni citokini. (<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>, <xref ref-type="bibr" rid="r20"><italic>20</italic></xref>) Serumski feritin se do sada u klini&#x010D;koj praksi pokazao kao pouzdan biomarker zaliha &#x017E;eljeza i izrazito koristan laboratorijski parametar u dijagnostici sideropeni&#x010D;nih anemija. (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>, <xref ref-type="bibr" rid="r15"><italic>15</italic></xref>)</p>
<p>Pored inicijalno opisanih karakteristika feritina, od 1970-ih sve vi&#x0161;e dolaze do izra&#x017E;aja njegove povi&#x0161;ene vrijednosti kod akutnih upalnih stanja, osobito onih s infektivnom etiologijom. (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>) S obzirom na to da se tijekom upale poja&#x010D;ano proizvodi u jetri i osloba&#x0111;a u cirkulaciju, uglavnom pod utjecajem proupalnih citokina IL-6 i tumor-nekrotiziraju&#x0107;eg &#x010D;imbenika alfa (engl. <italic>tumor necrosis factor-alpha,</italic> TNF-&#x03B1;), ukazuje na to da je on protein akutne faze. (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>, <xref ref-type="bibr" rid="r19"><italic>19</italic></xref>) Zaklju&#x010D;no se mo&#x017E;e re&#x0107;i da pove&#x0107;ane koncentracije feritina, osim &#x0161;to mogu upu&#x0107;ivati na suvi&#x0161;ak &#x017E;eljeza, mogu biti i pokazatelj upalnog statusa, &#x0161;to ga &#x010D;ini biomarkerom upale i infekcije. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>) Normalne vrijednosti serumskog feritina razlikuju se ovisno o spolu i laboratoriju u kojem je test u&#x010D;injen, ali obi&#x010D;no su deklarirani referentni intervali od 30 &#x2013; 300 &#x03BC;g/L za mu&#x0161;karce i od 10 &#x2013; 200 &#x03BC;g/L za &#x017E;ene. (<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>) Visoke vrijednosti feritina naj&#x010D;e&#x0161;&#x0107;e su indikativne za virusnu infekciju, a razine u serumu u sna&#x017E;noj su pozitivnoj korelaciji s razinom virusnog optere&#x0107;enja. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>)</p>
</sec>
<sec sec-type="other3">
<title>C-reaktivni protein</title>
<p>CRP je reaktant akutne faze &#x010D;ije se koncentracije u krvi zna&#x010D;ajno pove&#x0107;avaju nekoliko sati nakon infekcije ili ozljede tkiva te tijekom neinfektivnih upalnih stanja. Njegova glavna funkcija je sposobnost vezanja za fosfolipidne komponente o&#x0161;te&#x0107;enih stanica i fosfokolin na povr&#x0161;ini raznih patogena, rezultiraju&#x0107;i njihovom eliminacijom iz cirkulacije i tkiva. (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>) Otkriven je 1930. godine u serumu bolesnika oboljelih od pneumokokne pneumonije, a otkrili su ga lije&#x010D;nici William Smith Tillett (1892. &#x2013; 1974.) i Thomas Francis Jr. (1900. &#x2013; 1969.) s Rockefellerovog instituta za medicinska istra&#x017E;ivanja u New Yorku. (<xref ref-type="bibr" rid="r22"><italic>22</italic></xref>, <xref ref-type="bibr" rid="r23"><italic>23</italic></xref>) Ubraja se u proteine iz obitelji pentraksina koji &#x010D;ine humoralnu sastavnicu priro&#x0111;enog imunosnog sustava. (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>) Klini&#x010D;ku primjenu ima ve&#x0107; dugi niz godina kao vrlo osjetljiv, ali nespecifi&#x010D;an biljeg upale.</p>
<p>Produkcija i otpu&#x0161;tanje CRP-a u cirkulaciju posljedica su stimulacije proupalnim citokinima, ponajvi&#x0161;e IL-6, IL-1&#x03B2; i TNF-&#x03B1;. (<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>) Primarno mjesto sinteze CRP-a su hepatociti, a ekstrahepatalni izvori, poput stanica glatkih mi&#x0161;i&#x0107;a, makrofaga, limfocita i adipocita, jo&#x0161; uvijek nisu detaljno istra&#x017E;eni, no smatra se da ne pridonose zna&#x010D;ajno serumskim razinama. (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>, <xref ref-type="bibr" rid="r26"><italic>26</italic></xref>, <xref ref-type="bibr" rid="r27"><italic>27</italic></xref>) Do sada je poznato nekoliko izoformi CRP-a, me&#x0111;u kojima prevladavaju dvije: pentamerna forma ili &#x201E;nativni&#x201C; oblik CRP-a (engl. <italic>native C-reactive protein</italic>, nCRP) koji je prekursor monomerne forme ili &#x201E;modificiranog&#x201C; oblika CRP-a (engl. <italic>modified C-reactive protein</italic>, mCRP) s proupalnom ulogom. (<xref ref-type="bibr" rid="r27"><italic>27</italic></xref>, <xref ref-type="bibr" rid="r28"><italic>28</italic></xref>) nCRP je inicijalni oblik koji se osloba&#x0111;a iz jetre, a sastoji se od pet identi&#x010D;nih globularnih podjedinica me&#x0111;usobno povezanih nekovalentnim vezama u cikli&#x010D;ku strukturu diskoidnog oblika. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>, <xref ref-type="bibr" rid="r28"><italic>28</italic></xref>) Na mjestu upale, uz pomo&#x0107; aktiviranih trombocita, pentamerna forma ireverzibilno disocira u visoko aktivne monomerne forme, globularne podjedinice sastavljene od 206 aminokiselina, koje amplificiraju upalni odgovor. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>, <xref ref-type="bibr" rid="r27"><italic>27</italic></xref>)</p>
<p>Referentne vrijednosti CRP-a u serumu zdrave populacije ni&#x017E;e su od 5,0 mg/L. (<xref ref-type="bibr" rid="r29"><italic>29</italic></xref>) Nakon upalnog podra&#x017E;aja, koncentracije CRP-a po&#x010D;inju eksponencijalno rasti 4 &#x2013; 6 sati od njegova nastanka, vr&#x0161;ne vrijednosti dosti&#x017E;u unutar 48 sati, a nakon 72 sata po&#x010D;inju opadati te se normaliziraju oko sedmog dana po sanaciji upale. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>, <xref ref-type="bibr" rid="r31"><italic>31</italic></xref>) Poluvrijeme &#x017E;ivota CRP-a je konstantno i iznosi 19 sati, &#x0161;to zna&#x010D;i da su njegove serumske razine odre&#x0111;ene koli&#x010D;inom stvaranja, a smanjuju se nakon nestanka ili uklanjanja upalnog podra&#x017E;aja. (<xref ref-type="bibr" rid="r29"><italic>29</italic></xref>) Kao optimalna grani&#x010D;na vrijednost za dijagnozu infekcije definirana je koncentracija CRP-a od 50 &#x2013; 100 mg/L. (<xref ref-type="bibr" rid="r31"><italic>31</italic></xref>) Serumske razine CRP-a pokazale su se povezanima s ishodom antimikrobnog lije&#x010D;enja pa se tako porast CRP-a &#x2265;22 mg/L nakon 48 sati od uvo&#x0111;enja antimikrobne terapije povezuje s neu&#x010D;inkovito&#x0161;&#x0107;u primijenjene terapije, dok se pad CRP-a za 50 mg/L unutar &#x010D;etiri dana od po&#x010D;etka terapije povezuje s uspjehom lije&#x010D;enja. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) U kontekstu elektivne kirurgije, CRP vr&#x0161;ne koncentracije dosti&#x017E;e unutar 48 sati, a nakon 72 sata po&#x010D;inju opadati kod operacijskih zahvata nekompliciranog tijeka oporavka. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) Ako ne do&#x0111;e do pada vrijednosti CRP-a nakon tre&#x0107;ega poslijeoperacijskog dana, nego visoke vrijednosti perzistiraju i dalje, onda je takav nalaz indikativan za infekciju. (<xref ref-type="bibr" rid="r31"><italic>31</italic></xref>) Vrijednosti CRP-a koje, prema recentnim podatcima, upu&#x0107;uju na razvoj poslijeoperacijskih komplikacija jesu serumske razine CRP-a iznad 150 mg/L izme&#x0111;u tre&#x0107;eg i &#x010D;etvrtog dana nakon u&#x010D;injenoga kirur&#x0161;kog zahvata. (<xref ref-type="bibr" rid="r32"><italic>32</italic></xref>)</p>
</sec>
<sec sec-type="other4">
<title>Interleukin 6</title>
<p>IL-6 je citokin s dominantno proupalnim u&#x010D;inkom, a po sastavu je glikoprotein sa&#x010D;injen od 212 aminokiselina pri &#x010D;emu je 28 aminokiselina uklju&#x010D;eno u signalni peptid. (<xref ref-type="bibr" rid="r33"><italic>33</italic></xref>, <xref ref-type="bibr" rid="r34"><italic>34</italic></xref>) Do brzog pove&#x0107;anja njegove koncentracije dolazi u uvjetima stresa uslijed akutnih upalnih zbivanja zbog infekcije, prisutnosti kriti&#x010D;ne bolesti i o&#x0161;te&#x0107;enja tkiva traumatskom ozljedom ili operacijom. Sudjeluje kao glavni medijator u indukciji stvaranja proteina akutne faze, mobilizira neutrofilne progenitore iz ko&#x0161;tane sr&#x017E;i dovode&#x0107;i do periferne granulocitoze i poti&#x010D;e proliferaciju i diferencijaciju limfocita B i limfocita T zajedno sa stimulacijom produkcije imunoglobulina. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>&#x2013;<xref ref-type="bibr" rid="r37"><italic>37</italic></xref>) Otkrila ga je 1973. godine istra&#x017E;iva&#x010D;ka skupina sa Sveu&#x010D;ili&#x0161;ta u Osaki pod vodstvom japanskog imunologa Tadamitsu Kishimota. (<xref ref-type="bibr" rid="r38"><italic>38</italic></xref>) Iako je primarno identificiran kao protein koji stimulira limfocite B na proizvodnju protutijela (engl. <italic>B cell stimulatory factor 2</italic>, BSF-2), desetlje&#x0107;e kasnije su otkriveni njegovi pleotropni u&#x010D;inci te je 1988. godine slu&#x017E;beno preimenovan u IL-6. (<xref ref-type="bibr" rid="r34"><italic>34</italic></xref>, <xref ref-type="bibr" rid="r39"><italic>39</italic></xref>) Klini&#x010D;ki se primjenjuje kao nespecifi&#x010D;ni biljeg upale koji karakterizira povoljnija kinetika i korelacija s intenzitetom organske disfunkcije, zbog &#x010D;ega se pokazao kao koristan rani pokazatelj upalnog stanja i te&#x017E;ine bolesti. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>, <xref ref-type="bibr" rid="r40"><italic>40</italic></xref>)</p>
<p>IL-6, kao glavni induktor sinteze proteina akutne faze, sna&#x017E;no pozitivno korelira s CRP-om. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>) Sukladno tomu, promjene u cirkuliraju&#x0107;im razinama IL-6 odra&#x017E;avaju naknadne promjene u cirkuliraju&#x0107;im razinama CRP-a. Me&#x0111;utim, odre&#x0111;ivanje serumskih koncentracija IL-6 ne nalazi se u &#x0161;irokoj rutinskoj upotrebi kao odre&#x0111;ivanje CRP-a te se stoga CRP &#x010D;esto koristi kao surogat marker IL-6 kod razli&#x010D;itih klini&#x010D;kih entiteta. (<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>)</p>
<p>Normalne vrijednosti IL-6 u krvi zdravih pojedinaca izrazito su niske i kre&#x0107;u se ispod razine od 7 pg/mL. (<xref ref-type="bibr" rid="r37"><italic>37</italic></xref>) Tijekom upalne stimulacije izlu&#x010D;uju ga razli&#x010D;ite vrste stanica me&#x0111;u kojima su aktivirane imunosne stanice, stromalne stanice i hepatociti. (<xref ref-type="bibr" rid="r41"><italic>41</italic></xref>) Brzina i visina porasta cirkuliraju&#x0107;ih razina IL-6 razmjerno prati ozbiljnost bolesti i opseg o&#x0161;te&#x0107;enja tkiva, a time upu&#x0107;uje i na lo&#x0161;iji kona&#x010D;ni ishod bolesnika. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) Poluvrijeme &#x017E;ivota IL-6 iznosi 15 sati pa je u odnosu na druge upalne citokine, koji imaju daleko kra&#x0107;e poluvrijeme, prikladniji kao parametar za pra&#x0107;enje upalne aktivnosti i ima bolji prognosti&#x010D;ki potencijal. (<xref ref-type="bibr" rid="r42"><italic>42</italic></xref>) Kao grani&#x010D;ne vrijednosti za dijagnozu sindroma sustavnoga upalnog odgovora i sepse, predlo&#x017E;ene su koncentracije IL-6 od 40 pg/mL odnosno 100 pg/mL. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) U slu&#x010D;aju infekcije, povi&#x0161;ene serumske razine mogu se pratiti ve&#x0107; unutar dva sata od njenog po&#x010D;etka, a ako nastupi pad vrijednosti tijekom sljede&#x0107;ih 48 &#x2013; 72 sata, takav nalaz govori u prilog uspje&#x0161;no primijenjene terapije. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>, <xref ref-type="bibr" rid="r37"><italic>37</italic></xref>) U kontekstu elektivne kirurgije, vrijednosti IL-6 po&#x010D;inju rasti dva sata nakon incizije, vr&#x0161;ne koncentracije dosti&#x017E;u unutar 12 &#x2013; 24 sata, a nakon 48 &#x2013; 72 sata po&#x010D;inju opadati kod operacijskih zahvata nekompliciranog tijeka oporavka. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) Vrlo visoke vrijednosti IL-6 prvoga poslijeoperacijskog dana, kao i visoke vrijednosti CRP-a tre&#x0107;ega poslijeoperacijskog dana, prediktivne su za nastanak poslijeoperacijskih komplikacija. (<xref ref-type="bibr" rid="r43"><italic>43</italic></xref>) Iz svega navedenog mo&#x017E;e se zaklju&#x010D;iti da je IL-6 superiorniji u prepoznavanju poslijeoperacijskih komplikacija od CRP-a.</p>
</sec>
<sec sec-type="other5">
<title>Prokalcitonin</title>
<p>PCT je funkcionalni protein, sastavljen od 116 aminokiselina, koji se primarno sintetizira u C-stanicama &#x0161;titnja&#x010D;e kao prekursor kalcitonina, hormona uklju&#x010D;enog u regulaciju kalcija. (<xref ref-type="bibr" rid="r44"><italic>44</italic></xref>) Povijesno, prvi put se spominje 1975. godine u studiji koju su originalno objavili &#x0161;panjolski istra&#x017E;iva&#x010D;i na &#x010D;elu s Fernandom Moyom. (<xref ref-type="bibr" rid="r45"><italic>45</italic></xref>) Naime, oni su prilikom istra&#x017E;ivanja biosinteze kalcitonina u ultimobranhijalnim &#x017E;lijezdama koko&#x0161;i otkrili postojanje prekursora kalcitonina kojeg su nazvali prokalcitonin. (<xref ref-type="bibr" rid="r46"><italic>46</italic></xref>) Tek su 1993. godine Marcel Assicot i njegovi suradnici prvi dokazali da su serumske razine PCT-a povi&#x0161;ene u bolesnika s bakterijskom infekcijom i sepsom. (<xref ref-type="bibr" rid="r45"><italic>45</italic></xref>, <xref ref-type="bibr" rid="r47"><italic>47</italic></xref>) Od tada je PCT u&#x0161;ao u klini&#x010D;ku laboratorijsku primjenu kao biljeg za dijagnostiku i pra&#x0107;enje infekcija.</p>
<p>Fiziolo&#x0161;ki se gotovo u cijelosti konvertira u kalcitonin te se u cirkulaciji zdravih ljudi nalazi u vrlo niskim koncentracijama (&#x2264;0,1 ng/mL). (<xref ref-type="bibr" rid="r48"><italic>48</italic></xref>, <xref ref-type="bibr" rid="r49"><italic>49</italic></xref>) U patolo&#x0161;kim uvjetima, bilo zbog izravne stimulacije bakterijskim endotoksinima ili neizravne stimulacije upalnim medijatorima poput IL-6, TNF-&#x03B1; i IL-1&#x03B2;, uslijed upalnog odgovora na infekciju, dolazi do njegovog pove&#x0107;anog stvaranja u ekstratiroidnim tkivima i leukocitima. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r48"><italic>48</italic></xref>, <xref ref-type="bibr" rid="r50"><italic>50</italic></xref>) Ekstratiroidno sintetiziran PCT nema mogu&#x0107;nost pretvorbe u kalcitonin zbog &#x010D;ega su njegove serumske razine vi&#x0161;estruko povi&#x0161;ene kod bolesnika s bakterijskom infekcijom. (<xref ref-type="bibr" rid="r31"><italic>31</italic></xref>, <xref ref-type="bibr" rid="r44"><italic>44</italic></xref>) Isto tako, iako u znatno manjoj mjeri, razine PCT-a mogu biti pove&#x0107;ane i zbog neinfektivnih uzroka kao &#x0161;to su neki maligni neuroendokrini tumori (npr. sitnostani&#x010D;ni karcinom plu&#x0107;a, medularni karcinom &#x0161;titnja&#x010D;e, neuroendokrini tumori gastrointestinalnog trakta), akutna klini&#x010D;ka stanja (nr. sr&#x010D;ani arest, pankreatitis, rabdomioliza, te&#x0161;ka trauma) i poslijeoperacijski, posebno kod kirur&#x0161;kih zahvata na crijevima. (<xref ref-type="bibr" rid="r31"><italic>31</italic></xref>)</p>
<p>PCT se u svakodnevnoj klini&#x010D;koj praksi koristi kao indikator bakterijske infekcije i rani dijagnosti&#x010D;ki biomarker sepse. Osim &#x0161;to poma&#x017E;e u razlu&#x010D;ivanju bakterijske infekcije od upalnih stanja druge etiologije, dobro korelira s te&#x017E;inom bolesti te je koristan za prilago&#x0111;avanje antimikrobne terapije sa svrhom kvalitetnijega terapijskog zbrinjavanja bolesnika i racionalne primjene antibiotika. (<xref ref-type="bibr" rid="r44"><italic>44</italic></xref>) Prema algoritmu za kriti&#x010D;no oboljele bolesnike u JIM-u, koji objedinjuje klini&#x010D;ku evaluaciju i koncentracije PCT-a, zapo&#x010D;injanje antibiotskom terapijom preporu&#x010D;uje se u bolesnika s razinama PCT-a &#x2265;0,5 ng/mL, a prekidanje kad se razine PCT normaliziraju ili do&#x0111;e do njihova smanjenja za 80%. (<xref ref-type="bibr" rid="r51"><italic>51</italic></xref>)</p>
<p>Vrijeme indukcije PCT-a dulje je od citokina, ali kra&#x0107;e od CRP-a pa se u plazmi detektira ve&#x0107; nakon 3 &#x2013; 4 sata od po&#x010D;etka infekcije, dok vr&#x0161;ne koncentracije posti&#x017E;e u razdoblju od 6 &#x2013; 12 sati i ostaje povi&#x0161;en sve dok traje upalni proces. (<xref ref-type="bibr" rid="r50"><italic>50</italic></xref>) Ovisno o izmjerenim koncentracijama, vrijednosti PCT-a &lt;0,5 ng/mL isklju&#x010D;uju vjerojatnost sustavne infekcije, vrijednosti izme&#x0111;u 2 &#x2013; 10 ng/mL indikativne su za sepsu, a vrijednosti &#x2265;10 ng/mL povezane su sa septi&#x010D;nim &#x0161;okom i razvojem komplikacija. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r50"><italic>50</italic></xref>) Za razliku od visokih vrijednosti PCT-a kod bolesnika sa sustavnom upalnom reakcijom na bakterijsku infekciju, kod bolesnika s virusnom bolesti, upalom neinfektivne etiologije ili lokalnom infekcijom, koncentracije PCT-a su blago povi&#x0161;ene (&lt;2 ng/mL). (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r49"><italic>49</italic></xref>, <xref ref-type="bibr" rid="r50"><italic>50</italic></xref>) Poluvrijeme &#x017E;ivota PCT-a je dugo, u prosjeku oko 24 sata. (<xref ref-type="bibr" rid="r52"><italic>52</italic></xref>) Stoga, ako nakon primjene antibiotske terapije do&#x0111;e do smanjenja plazmatskih razina PCT-a za 50% tijekom 24 sata, to bi zna&#x010D;ilo u&#x010D;inkovito antimikrobno lije&#x010D;enje. (<xref ref-type="bibr" rid="r44"><italic>44</italic></xref>) U kontekstu elektivne kirurgije, zanimljiva je vrijednost PCT-a kao prediktivnog biljega infektivnih komplikacija. Njegove povi&#x0161;ene koncentracije tre&#x0107;ega poslijeoperacijskog dana, osim &#x0161;to dobro koreliraju s pojavom poslijeoperacijskih infekcija, u abdominalnoj kirurgiji ukazuju na popu&#x0161;tanje anastomoza. (<xref ref-type="bibr" rid="r31"><italic>31</italic></xref>)</p>
</sec>
<sec sec-type="other6">
<title>&#x0160;irina distribucije monocita</title>
<p>MDW je novi hematolo&#x0161;ki parametar s obe&#x0107;avaju&#x0107;im rezultatima kao rani biomarker infekcije i sepse. Predstavlja kvantitativnu mjeru promjena volumena cirkuliraju&#x0107;ih monocita koje se doga&#x0111;aju tijekom rane faze infekcije kao rezultat njihove aktivacije izazvane patogenima. (<xref ref-type="bibr" rid="r53"><italic>53</italic></xref>, <xref ref-type="bibr" rid="r54"><italic>54</italic></xref>) Na proupalni infektivni podra&#x017E;aj monociti reagiraju odre&#x0111;enim morfolo&#x0161;kim i funkcionalnim promjenama, zbog &#x010D;ega se u sepsi mo&#x017E;e identificirati nekoliko razli&#x010D;itih monocitnih subpopulacija. (<xref ref-type="bibr" rid="r55"><italic>55</italic></xref>) Stoga, &#x0161;to je ve&#x0107;a morfolo&#x0161;ka heterogenost monocita, to je ve&#x0107;a i vrijednost MDW-a. Optimalna grani&#x010D;na vrijednost MDW-a odre&#x0111;ena za detekciju sepse je &gt;21,5, ako su uzroci venske krvi prikupljeni u spremnike s trikalij etilendiamintetraoctenom kiselinom (engl. <italic>tripotassium ethylenediaminetetraacetic acid</italic>, K<sub>3</sub>EDTA), odnosno &gt;20,0 ako su kori&#x0161;teni K<sub>2</sub>EDTA spremnici. (<xref ref-type="bibr" rid="r56"><italic>56</italic></xref>)</p>
<p>MDW je jednostavan klini&#x010D;ki test koji se odre&#x0111;uje iz rutinske pretrage kompletne krvne slike s diferencijalnom krvnom slikom na specijaliziranom automatskom hematolo&#x0161;kom analizatoru. Rije&#x010D; je o brzo i lako dostupnom parametru, &#x010D;ije rezultate ne treba dugo &#x010D;ekati s obzirom na to da su nalazi krvne slike gotovi ranije od biokemijskih pretraga. Od 2019. godine odobren je od strane US FDA kao rani indikator sepse u odraslih bolesnika zaprimljenih na odjel hitne medicinske slu&#x017E;be. (<xref ref-type="bibr" rid="r54"><italic>54</italic></xref>, <xref ref-type="bibr" rid="r57"><italic>57</italic></xref>) Do sada se dijagnosti&#x010D;ka to&#x010D;nost MDW-a pokazala usporedivom s konvencionalno dostupnim markerima sepse, &#x0161;tovi&#x0161;e posebno u&#x010D;inkovitim se pokazao dijagnosti&#x010D;ki model koji obuhva&#x0107;a kombinaciju MDW-a kao ranog indikatora u prepoznavanju sepse te CRP-a i PCT-a kao potvrdnih indikatora. (<xref ref-type="bibr" rid="r54"><italic>54</italic></xref>, <xref ref-type="bibr" rid="r58"><italic>58</italic></xref>)</p>
</sec>
<sec sec-type="other7">
<title>Presepsin</title>
<p>Kad govorimo o presepsinu, onda govorimo o biljegu koji reflektira aktivaciju monocita i makrofaga kao posljedicu infektivnog podra&#x017E;aja. (<xref ref-type="bibr" rid="r59"><italic>59</italic></xref>) Presepsin je fragment topivog oblika biljega CD14 (engl. <italic>soluble CD14 subtype</italic>, sCD14-ST). Biljeg CD14 je glikoproteinski receptor smje&#x0161;ten na povr&#x0161;ini membrana mononuklearnih stanica (monocita i makrofaga) koji ima visoki kapacitet za vezanje lipopolisaharida. (<xref ref-type="bibr" rid="r60"><italic>60</italic></xref>) Mo&#x017E;e postojati u dva oblika, od kojih je jedan vezan za membranu (engl. <italic>membrane bound CD14</italic>, mCD14), a drugi je prisutan u plazmi kao topivi oblik (engl. <italic>soluble form CD14</italic>, sCD14). (<xref ref-type="bibr" rid="r61"><italic>61</italic></xref>) U plazmi sCD14 podlije&#x017E;e proteolizi katepsinom D te time nastaje polipeptidni fragment veli&#x010D;ine 13 kDa, poznatiji kao presepsin. (<xref ref-type="bibr" rid="r59"><italic>59</italic></xref>, <xref ref-type="bibr" rid="r61"><italic>61</italic></xref>) Otkriven je 2004. godine, kad je znanstvena skupina japanskih istra&#x017E;iva&#x010D;a pod vodstvom Yasunorija Yaegashija sa Sveu&#x010D;ili&#x0161;ta Iwate u Morioki prona&#x0161;la do tada nepoznati oblik sCD14, &#x010D;ije su razine povi&#x0161;ene u bolesnika sa sepsom u usporedbi s bolesnicima sa sindromom sustavnoga upalnog odgovora (engl. <italic>systemic inflammatory response syndrome</italic>, SIRS) i zdravim kontrolama. (<xref ref-type="bibr" rid="r60"><italic>60</italic></xref>, <xref ref-type="bibr" rid="r62"><italic>62</italic></xref>) Pokazalo se da je visoko specifi&#x010D;an za bakterijske infekcije, a njegovo pove&#x0107;anje se detektira vrlo rano tijekom septi&#x010D;nog stanja te se danas smatra vrijednim markerom u ranoj dijagnozi, procjeni te&#x017E;ine bolesti i prognozi sepse. (<xref ref-type="bibr" rid="r62"><italic>62</italic></xref>, <xref ref-type="bibr" rid="r63"><italic>63</italic></xref>) Sli&#x010D;no prethodno opisanim biljezima, pove&#x0107;anje njegovih koncentracija, osim kod bakterijskih infekcija, mo&#x017E;e se na&#x0107;i i u kriti&#x010D;nim bolestima neinfektivnog podrijetla, ali uz osnovnu razliku da to pove&#x0107;anje nije zna&#x010D;ajno. (<xref ref-type="bibr" rid="r64"><italic>64</italic></xref>)</p>
<p>Presepsin odlikuje brza kinetika tako da se porast njegovih plazmatskih razina bilje&#x017E;i ve&#x0107; unutar dva sata od infekcije, vr&#x0161;ne koncentracije posti&#x017E;e nakon tri sata i ima vrlo kratko poluvrijeme &#x017E;ivota koje iznosi izme&#x0111;u &#x010D;etiri i pet sati. (<xref ref-type="bibr" rid="r65"><italic>65</italic></xref>) Spomenute karakteristike &#x010D;ine ga superiornim u odnosu na uobi&#x010D;ajeno kori&#x0161;tene biljege upale u smislu ranije detekcije infektivnog zbivanja i adekvatnije prilagodbe terapije. U serumu zdravih ljudi nalazi se u vrlo niskim koncentracijama, a grani&#x010D;ne vrijednosti presepsina relevantne za interpretaciju u kontekstu sepse su &lt;200 pg/mL za isklju&#x010D;enje te interval izme&#x0111;u 400 &#x2013; 600 pg/mL za potvrdnu dijagnozu. (<xref ref-type="bibr" rid="r65"><italic>65</italic></xref>, <xref ref-type="bibr" rid="r66"><italic>66</italic></xref>)</p>
</sec>
<sec sec-type="other8">
<title>Protein pankreasnog kamenca</title>
<p>PSP, tako&#x0111;er poznat i kao litostatin ili regeneracijski protein 1 alfa, jest glikoprotein sastavljen od 144 aminokiseline koji se najve&#x0107;im dijelom sintetizira u acinusnim stanicama gu&#x0161;tera&#x010D;e, zatim beta-stanicama Langerhansovih oto&#x010D;i&#x0107;a, intestinalnim Panethovim stanicama te stanicama fundusa &#x017E;eluca. (<xref ref-type="bibr" rid="r67"><italic>67</italic></xref>, <xref ref-type="bibr" rid="r68"><italic>68</italic></xref>) Za njegovo otkri&#x0107;e zaslu&#x017E;no je nekoliko neovisnih istra&#x017E;iva&#x010D;kih skupina koje su se bavile istra&#x017E;ivanjima patologije pankreatitisa i dijabetesa u razdoblju 1970-ih godina. (<xref ref-type="bibr" rid="r69"><italic>69</italic></xref>, <xref ref-type="bibr" rid="r70"><italic>70</italic></xref>) Iako se jo&#x0161; uvijek istra&#x017E;uje, utvr&#x0111;en je kao indikator stresa i sve se vi&#x0161;e koristi kao biomarker za ranu dijagnozu sepse prije pojave klini&#x010D;kih simptoma. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r67"><italic>67</italic></xref>)</p>
<p>U vrijeme otkri&#x0107;a, vjerovalo se da je funkcija PSP-a povezana s inhibicijom stvaranja kamenaca u gu&#x0161;tera&#x010D;i. Danas je poznato da je povezan s upalnim promjenama gu&#x0161;tera&#x010D;e i da su njegove razine umjereno povi&#x0161;ene u bolesnika s dijabetesom tipa II i prate&#x0107;im kroni&#x010D;nim komplikacijama, ali njegova funkcija jo&#x0161; uvijek nije do kraja razja&#x0161;njena. (<xref ref-type="bibr" rid="r67"><italic>67</italic></xref>, <xref ref-type="bibr" rid="r71"><italic>71</italic></xref>, <xref ref-type="bibr" rid="r72"><italic>72</italic></xref>) Novija istra&#x017E;ivanja pokazala su da se poja&#x010D;ano izlu&#x010D;uje tijekom upalnih stanja ekstrapankreati&#x010D;nog podrijetla i u uvjetima stresa te da djeluje kao reaktant akutne faze. (<xref ref-type="bibr" rid="r71"><italic>71</italic></xref>, <xref ref-type="bibr" rid="r72"><italic>72</italic></xref>) Recentno objavljeni podatci isti&#x010D;u da PSP, u kontekstu sepse, ima podjednaku dijagnosti&#x010D;ku osjetljivost kao CRP, IL-6 i PCT i ve&#x0107;u dijagnosti&#x010D;ku specifi&#x010D;nost od PCT-a. (<xref ref-type="bibr" rid="r70"><italic>70</italic></xref>) Usporedba izme&#x0111;u biomarkera prikazana je u <xref ref-type="table" rid="t1">Table 1</xref>. U zdrave populacije granice referentnog intervala se kre&#x0107;u izme&#x0111;u 10 i 15 ng/mL, a za klini&#x010D;ku upotrebu u dijagnozi infekcije hospitaliziranih bolesnika odre&#x0111;ena je grani&#x010D;na vrijednost od 44,18 ng/mL. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r71"><italic>71</italic></xref>)</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Comparison of inflammatory biomarkers (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>, <xref ref-type="bibr" rid="r37"><italic>37</italic></xref>, <xref ref-type="bibr" rid="r50"><italic>50</italic></xref>, <xref ref-type="bibr" rid="r59"><italic>59</italic></xref>, <xref ref-type="bibr" rid="r65"><italic>65</italic></xref>, <xref ref-type="bibr" rid="r70"><italic>70</italic></xref>)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="16.58%"/>
<col width="18.94%"/>
<col width="18.93%"/>
<col width="20.7%"/>
<col width="24.85%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Upalni biomarker<break/>/ Inflammatory biomarker</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Osjetljivost za utvr&#x0111;ivanje infekcije<break/>/ Sensitivity to detect infection</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Specifi&#x010D;nost za utvr&#x0111;ivanje infekcije<break/>/ Specificity to detect infection</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Prognosti&#x010D;ki &#x010D;imbenik<break/>/ Prognostic factor</th>
<th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Detektabilnost nakon infektivnog podra&#x017E;aja<break/>/ Detectability after infective stimulus</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">CRP</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">++++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">+</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">+</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">4 &#x2013; 6 h</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">IL-6</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">++++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">+++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&lt; 2 h</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">PCT</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">++++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">+++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">3 &#x2013; 4 h</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Presepsin</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">++++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">+++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">++++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">2 h</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">PSP</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">++++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">++++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">++++</td>
<td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">Rano tijekom infekcije &#x2013; to&#x010D;no vrijeme nije odre&#x0111;eno<break/>/ Early during infection &#x2013; exact time not determined</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p>CRP &#x2013; C-reaktivni protein / C-reactive protein; IL-6 &#x2013; interleukin 6 / interleukin-6; PCT &#x2013; prokalcitonin / procalcitonin; PSP &#x2013; protein pankreasnog kamenca / pancreatic stone protein</p>
</table-wrap-foot></table-wrap>
</sec>
<sec sec-type="other9">
<title>Zaklju&#x010D;ak</title>
<p>Upalna stanja se smatraju ozbiljnim problemom i rano prepoznavanje infektivne etiologije velik je izazov u intenzivnoj medicini. Postavljanje pravovremene dijagnoze i lije&#x010D;enje sepse, kao &#x017E;ivotno ugro&#x017E;avaju&#x0107;eg stanja s visokom stopom pobola i smrtnosti, od iznimnog je zna&#x010D;enja za pobolj&#x0161;anje ishoda. Strategija kori&#x0161;tenja biomarkera upale i njihove interpretacije u sklopu klini&#x010D;kih pokazatelja omogu&#x0107;uju dobivanje klju&#x010D;nih informacija za postizanje tog cilja i &#x010D;ine temelj personaliziranog pristupa svakom kriti&#x010D;no oboljelom bolesniku. Iako istra&#x017E;ivanja na podru&#x010D;ju biljega upale bilje&#x017E;e kontinuirani napredak, jo&#x0161; uvijek ne postoji samostalni biomarker koji je validiran za definitivnu dijagnozu sepse.</p>
<sec>
<title>Kratice</title>
<p>BSF-2 &#x010D;imbenik stimulacije B-stanica 2, engl. <italic>B cell stimulatory factor 2</italic></p>
<p>CD povr&#x0161;inski membranski biljezi za razlikovanje leukocita, engl. <italic>cluster of differentiation</italic></p>
<p>CRP C-reaktivni protein</p>
<p>FDA Ameri&#x010D;ka agencija za hranu i lijekove, engl. <italic>U.S. Food and Drug Administration</italic></p>
<p>ICU engl. <italic>intensive care unit</italic></p>
<p>IL-6 interleukin 6</p>
<p>JIM jedinica intenzivne medicine</p>
<p>K<sub>3</sub>EDTA trikalij etilendiamintetraoctena kiselina, engl. <italic>tripotassium ethylenediaminetetraacetic acid</italic></p>
<p>mCD14 biljeg CD14 vezan za membranu, engl. <italic>membrane bound CD14</italic></p>
<p>mCRP &#x201E;modificirani&#x201C; oblik C-reaktivnog proteina, engl. <italic>modified C-reactive protein</italic></p>
<p>MDW &#x0161;irina distribucije monocita, engl. <italic>monocyte distribution width</italic></p>
<p>nCRP &#x201E;nativni&#x201C; oblik C-reaktivnog proteina, engl. <italic>native C-reactive protein</italic></p>
<p>NIH Nacionalni institut za zdravlje, engl. <italic>National Institutes of Health</italic></p>
<p>NLR neutrofilno/limfocitni omjer, engl. <italic>neutrophil to lymphocyte ratio</italic></p>
<p>PCT prokalcitonin, engl. <italic>procalcitonin</italic></p>
<p>PSP protein pankreasnog kamenca, engl. <italic>pancreatic stone protein</italic></p>
<p>sCD14 topljivi oblik biljega CD14, engl. <italic>soluble form CD14</italic></p>
<p>sCD14-ST podtip topljivog oblika biljega CD14, engl. <italic>soluble CD14 subtype</italic></p>
<p>SIRS sindrom sustavnoga upalnog odgovora, engl. <italic>systemic inflammatory response syndrome</italic></p>
<p>TNF-&#x03B1; tumor-nekrotiziraju&#x0107;i &#x010D;imbenik alfa, engl. <italic>tumor necrosis factor-alpha</italic></p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<p content-type="fn-title">INFORMACIJE O SUKOBU INTERESA</p>
<p>Autori nisu deklarirali sukob interesa relevantan za ovaj rad.</p>
</fn>
<fn fn-type="financial-disclosure">
<p content-type="fn-title">INFORMACIJA O FINANCIRANJU</p>
<p>Za ovaj &#x010D;lanak nisu primljena financijska sredstva.</p>
</fn>
</fn-group>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x00E9;ndez Hern&#x00E1;ndez</surname><given-names>R</given-names></name><name><surname>Ramasco Rueda</surname><given-names>F</given-names></name></person-group>. <article-title>Biomarkers as prognostic predictors and therapeutic guide in critically ill patients: clinical evidence.</article-title> <source>J Pers Med</source>. <year>2023</year>;<volume>13</volume>(<issue>2</issue>):<fpage>333</fpage>.<pub-id pub-id-type="pmid">36836567</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name></person-group>. <article-title>Biomarkers in intensive care unit infections, friend or foe?</article-title> <source>J Emerg Crit Care Med</source>. <year>2019</year>;<volume>3</volume>:<fpage>27</fpage>.</mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Grimberg</surname><given-names>DC</given-names></name><name><surname>Inman</surname><given-names>BA</given-names></name></person-group>. <article-title>Classification of molecular biomarkers.</article-title> <source>Soc Int Urol J.</source> <year>2020</year>;<volume>1</volume>(<issue>1</issue>):<fpage>8</fpage>&#x2013;<lpage>15</lpage>.</mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neves</surname><given-names>CS</given-names></name><name><surname>Moura</surname><given-names>LCRV</given-names></name><name><surname>Da Costa Lima</surname><given-names>JL</given-names></name><name><surname>Maciel</surname><given-names>MAV</given-names></name></person-group>. <article-title>Clinical outcomes of intensive care unit patients infected with multidrug-resistant gram-negative bacteria treated with ceftazidime/avibactam and ceftolozane/tazobactam.</article-title> <source>Braz J Microbiol</source>. <year>2024</year>;<volume>55</volume>(<issue>1</issue>):<fpage>333</fpage>&#x2013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">38133795</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heffernan</surname><given-names>AJ</given-names></name><name><surname>Denny</surname><given-names>KJ</given-names></name></person-group>. <article-title>Host diagnostic biomarkers of infection in the ICU: where are we and where are we going?</article-title> <source>Curr Infect Dis Rep</source>. <year>2021</year>;<volume>23</volume>(<issue>4</issue>):<fpage>4</fpage>.<pub-id pub-id-type="pmid">33613126</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x00F3;voa</surname><given-names>P</given-names></name><name><surname>Coelho</surname><given-names>L</given-names></name></person-group>. <article-title>Which biomarkers can be used as diagnostic tools for infection in suspected sepsis?</article-title> <source>Semin Respir Crit Care Med</source>. <year>2021</year>;<volume>42</volume>(<issue>5</issue>):<fpage>662</fpage>&#x2013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">34544183</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Artigas</surname><given-names>A</given-names></name><name><surname>Ferrer</surname><given-names>R</given-names></name></person-group>. <article-title>Biomarkers in the ICU: less is more?</article-title> <source>Intensive Care Med.</source> <year>2021</year>;<volume>47</volume>(<issue>1</issue>):<fpage>97</fpage>&#x2013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">33057749</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Geng</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Shan</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group>. <article-title>Ferritin and procalcitonin serve as discriminative inflammatory biomarkers and can predict the prognosis of severe fever with thrombocytopenia syndrome in its early stages.</article-title> <source>Front Microbiol</source>. <year>2023</year>;<volume>14</volume>:<elocation-id>1168381</elocation-id>.<pub-id pub-id-type="pmid">37143532</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farkas</surname><given-names>JD</given-names></name></person-group>. <article-title>The complete blood count to diagnose septic shock.</article-title> <source>J Thorac Dis</source>. <year>2020</year>;<volume>12</volume> <supplement>Suppl 1</supplement>:<fpage>S16</fpage>&#x2013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">32148922</pub-id></mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watt</surname><given-names>DG</given-names></name><name><surname>Horgan</surname><given-names>PG</given-names></name><name><surname>McMillan</surname><given-names>DC</given-names></name></person-group>. <article-title>Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: a systematic review.</article-title> <source>Surgery</source>. <year>2015</year>;<volume>157</volume>(<issue>2</issue>):<fpage>362</fpage>&#x2013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">25616950</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>T</given-names></name><name><surname>Uehara</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>G</given-names></name><name><surname>Arai</surname><given-names>S</given-names></name><name><surname>Sugano</surname><given-names>M</given-names></name></person-group>. <article-title>Neutrophil left shift and white blood cell count as markers of bacterial infection.</article-title> <source>Clin Chim Acta</source>. <year>2016</year>;<volume>457</volume>:<fpage>46</fpage>&#x2013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">27034055</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buonacera</surname><given-names>A</given-names></name><name><surname>Stancanelli</surname><given-names>B</given-names></name><name><surname>Colaci</surname><given-names>M</given-names></name><name><surname>Malatino</surname><given-names>L</given-names></name></person-group>. <article-title>Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases.</article-title> <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>(<issue>7</issue>):<fpage>3636</fpage>.<pub-id pub-id-type="pmid">35408994</pub-id></mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahorec</surname><given-names>R</given-names></name></person-group>. <article-title>Neutrophil-to-lymphocyte ratio, past, present and future perspectives.</article-title> <source>Bratisl Lek Listy</source>. <year>2021</year>;<volume>122</volume>(<issue>7</issue>):<fpage>474</fpage>&#x2013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">34161115</pub-id></mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemaire</surname><given-names>B</given-names></name><name><surname>Frias</surname><given-names>MA</given-names></name><name><surname>Golaz</surname><given-names>O</given-names></name><name><surname>Magnin</surname><given-names>JL</given-names></name><name><surname>Viette</surname><given-names>V</given-names></name><name><surname>Vuilleumier</surname><given-names>N</given-names></name><etal/></person-group> <article-title>Ferritin: a biomarker requiring caution in clinical decision.</article-title> <source>Diagnostics (Basel)</source>. <year>2024</year>;<volume>14</volume>(<issue>4</issue>):<fpage>386</fpage>.<pub-id pub-id-type="pmid">38396425</pub-id></mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkhateeb</surname><given-names>AA</given-names></name><name><surname>Connor</surname><given-names>JR</given-names></name></person-group>. <article-title>The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis.</article-title> <source>Biochim Biophys Acta</source>. <year>2013</year>;<volume>1836</volume>(<issue>2</issue>):<fpage>245</fpage>&#x2013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">23891969</pub-id></mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahroum</surname><given-names>N</given-names></name><name><surname>Alghory</surname><given-names>A</given-names></name><name><surname>Kiyak</surname><given-names>Z</given-names></name><name><surname>Alwani</surname><given-names>A</given-names></name><name><surname>Seida</surname><given-names>R</given-names></name><name><surname>Alrais</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Ferritin &#x2013; from iron, through inflammation and autoimmunity, to COVID-19.</article-title> <source>J Autoimmun</source>. <year>2022</year>;<volume>126</volume>:<elocation-id>102778</elocation-id>.<pub-id pub-id-type="pmid">34883281</pub-id></mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheftel</surname><given-names>AD</given-names></name><name><surname>Mason</surname><given-names>AB</given-names></name><name><surname>Ponka</surname><given-names>P</given-names></name></person-group>. <article-title>The long history of iron in the universe and in health and disease.</article-title> <source>Biochim Biophys Acta</source>. <year>2012</year>;<volume>1820</volume>(<issue>3</issue>):<fpage>161</fpage>&#x2013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2011.08.002</pub-id><pub-id pub-id-type="pmid">21856378</pub-id></mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulvik</surname><given-names>RJ</given-names></name></person-group>. <article-title>Hereditary haemochromatosis through 150 years.</article-title> <source>Tidsskr Nor Laegeforen</source>. <year>2016</year>;<volume>136</volume>(<issue>23&#x2013;24</issue>):<fpage>2017</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.4045/tidsskr.15.1003</pub-id><pub-id pub-id-type="pmid">28004554</pub-id></mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Knovich</surname><given-names>MA</given-names></name><name><surname>Coffman</surname><given-names>LG</given-names></name><name><surname>Torti</surname><given-names>FM</given-names></name><name><surname>Torti</surname><given-names>SV</given-names></name></person-group>. <article-title>Serum ferritin: past, present and future.</article-title> <source>Biochim Biophys Acta</source>. <year>2010</year>;<volume>1800</volume>(<issue>8</issue>):<fpage>760</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2010.03.011</pub-id><pub-id pub-id-type="pmid">20304033</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>N</given-names></name></person-group>. <article-title>The relationship between serum ferritin level and clinical outcomes in sepsis based on a large public database.</article-title> <source>Sci Rep</source>. <year>2023</year>;<volume>13</volume>(<issue>1</issue>):<fpage>8677</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-023-35874-2</pub-id><pub-id pub-id-type="pmid">37248291</pub-id></mixed-citation></ref>
<ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabay</surname><given-names>C</given-names></name><name><surname>Kushner</surname><given-names>I</given-names></name></person-group>. <article-title>Acute-phase proteins and other systemic responses to inflammation.</article-title> <source>N Engl J Med</source>. <year>1999</year>;<volume>340</volume>(<issue>6</issue>):<fpage>448</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199902113400607</pub-id><pub-id pub-id-type="pmid">9971870</pub-id></mixed-citation></ref>
<ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>HS</given-names></name></person-group>. <article-title>William Smith Tillett, 1892&#x2013;1974.</article-title> <source>J Infect Dis</source>. <year>1974</year>;<volume>130</volume>(<issue>3</issue>):<fpage>311</fpage>&#x2013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/130.3.311</pub-id><pub-id pub-id-type="pmid">4607358</pub-id></mixed-citation></ref>
<ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez</surname><given-names>RV</given-names></name><name><surname>Szalai</surname><given-names>AJ</given-names></name></person-group>. <article-title>Therapeutic lowering of C-reactive protein.</article-title> <source>Front Immunol</source>. <year>2021</year>;<volume>11</volume>:<elocation-id>619564</elocation-id>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.619564</pub-id><pub-id pub-id-type="pmid">33633738</pub-id></mixed-citation></ref>
<ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottazzi</surname><given-names>B</given-names></name><name><surname>Doni</surname><given-names>A</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group>. <article-title>An integrated view of humoral innate immunity: pentraxins as a paradigm.</article-title> <source>Annu Rev Immunol</source>. <year>2010</year>;<volume>28</volume>:<fpage>157</fpage>&#x2013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-030409-101305</pub-id><pub-id pub-id-type="pmid">19968561</pub-id></mixed-citation></ref>
<ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>SB</given-names></name><name><surname>Cecchin</surname><given-names>A</given-names></name><name><surname>Lucchesi</surname><given-names>C</given-names></name><name><surname>Putty</surname><given-names>T</given-names></name><name><surname>Edwards</surname><given-names>S</given-names></name><name><surname>Petrou</surname><given-names>T</given-names></name><etal/></person-group> <article-title>Can C-reactive protein be used as a surrogate marker of IL-6 in a broad array of clinical entities?</article-title> <source>Biomark Med</source>. <year>2023</year>;<volume>17</volume>(<issue>24</issue>):<fpage>1001</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.2217/bmm-2023-0708</pub-id><pub-id pub-id-type="pmid">38235562</pub-id></mixed-citation></ref>
<ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Zehra</surname><given-names>A</given-names></name><name><surname>Khalid</surname><given-names>MU</given-names></name><name><surname>Hassan</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>SIA</given-names></name></person-group>. <article-title>Role of C-reactive protein in disease progression, diagnosis and management.</article-title> <source>Discoveries (Craiova)</source>. <year>2023</year>;<volume>11</volume>(<issue>4</issue>):<elocation-id>e179</elocation-id>. <pub-id pub-id-type="doi">10.15190/d.2023.18</pub-id><pub-id pub-id-type="pmid">39554800</pub-id></mixed-citation></ref>
<ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouliou</surname><given-names>DS</given-names></name></person-group>. <article-title>C-reactive protein: pathophysiology, diagnosis, false test results and a novel diagnostic algorithm for clinicians.</article-title> <source>Diseases</source>. <year>2023</year>;<volume>11</volume>(<issue>4</issue>):<fpage>132</fpage>. <pub-id pub-id-type="doi">10.3390/diseases11040132</pub-id><pub-id pub-id-type="pmid">37873776</pub-id></mixed-citation></ref>
<ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>ME</given-names></name><name><surname>Hornick</surname><given-names>MG</given-names></name><name><surname>Stefanski</surname><given-names>A</given-names></name><name><surname>Albanna</surname><given-names>HR</given-names></name><name><surname>Gjoni</surname><given-names>A</given-names></name><name><surname>Hall</surname><given-names>GD</given-names></name><etal/></person-group> <article-title>A biofunctional review of C-reactive protein (CRP) as a mediator of inflammatory and immune responses: differentiating pentameric and modified CRP isoform effects.</article-title> <source>Front Immunol</source>. <year>2023</year>;<volume>14</volume>:<elocation-id>1264383</elocation-id>. <pub-id pub-id-type="doi">10.3389/fimmu.2023.1264383</pub-id><pub-id pub-id-type="pmid">37781355</pub-id></mixed-citation></ref>
<ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu&#x017E;ina Mi&#x0161;i&#x0107;</surname><given-names>D</given-names></name><name><surname>Zovak</surname><given-names>M</given-names></name><name><surname>Kopljar</surname><given-names>M</given-names></name><name><surname>&#x010C;i&#x010D;ek</surname><given-names>S</given-names></name><name><surname>Bili&#x0107;</surname><given-names>Z</given-names></name></person-group>. <article-title>Comparison of C-reactive protein levels in serum and peritoneal fluid in early diagnosis of anastomotic leakage after colorectal surgery.</article-title> <source>Acta Clin Croat</source>. <year>2023</year>;<volume>62</volume>(<issue>1</issue>):<fpage>11</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">38304380</pub-id></mixed-citation></ref>
<ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidhase</surname><given-names>L</given-names></name><name><surname>Wellh&#x00F6;fer</surname><given-names>D</given-names></name><name><surname>Schulze</surname><given-names>G</given-names></name><name><surname>Kaiser</surname><given-names>T</given-names></name><name><surname>Drogies</surname><given-names>T</given-names></name><name><surname>Wurst</surname><given-names>U</given-names></name><etal/></person-group> <article-title>Is interleukin-6 a better predictor of successful antibiotic therapy than procalcitonin and C-reactive protein? A single center study in critically ill adults.</article-title> <source>BMC Infect Dis</source>. <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>150</fpage>. <pub-id pub-id-type="doi">10.1186/s12879-019-3800-2</pub-id><pub-id pub-id-type="pmid">30760225</pub-id></mixed-citation></ref>
<ref id="r31"><label>31</label><mixed-citation publication-type="book">Binnie A, Lage J, Dos Santos CC. How can biomarkers be used to differentiate between infection and non-infectious causes of inflammation? U: Deutschman CS, Neligan PJ, ur. Evidence-based practice of critical care. 3 izd. Philadelphia: Elsevier; 2020, str. 319-24.</mixed-citation></ref>
<ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhayyan</surname><given-names>AM</given-names></name><name><surname>McSorley</surname><given-names>ST</given-names></name><name><surname>Kearns</surname><given-names>RJ</given-names></name><name><surname>Horgan</surname><given-names>PG</given-names></name><name><surname>Roxburgh</surname><given-names>CSD</given-names></name><name><surname>McMillan</surname><given-names>DC</given-names></name></person-group>. <article-title>The relationship between anaesthetic technique, clinicopathological characteristics and the magnitude of the postoperative systemic inflammatory response in patients undergoing elective surgery for colon cancer.</article-title> <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>(<issue>4</issue>):<elocation-id>e0228580</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0228580</pub-id><pub-id pub-id-type="pmid">32348308</pub-id></mixed-citation></ref>
<ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Br&#x00E1;bek</surname><given-names>J</given-names></name><name><surname>Jakubek</surname><given-names>M</given-names></name><name><surname>Vellieux</surname><given-names>F</given-names></name><name><surname>Novotn&#x00FD;</surname><given-names>J</given-names></name><name><surname>Kol&#x00E1;&#x0159;</surname><given-names>M</given-names></name><name><surname>Lacina</surname><given-names>L</given-names></name><etal/></person-group> <article-title>Interleukin-6: molecule in the intersection of cancer, ageing and COVID-19.</article-title> <source>Int J Mol Sci</source>. <year>2020</year>;<volume>21</volume>(<issue>21</issue>):<fpage>7937</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21217937</pub-id><pub-id pub-id-type="pmid">33114676</pub-id></mixed-citation></ref>
<ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trovato</surname><given-names>M</given-names></name><name><surname>Sciacchitano</surname><given-names>S</given-names></name><name><surname>Facciol&#x00E0;</surname><given-names>A</given-names></name><name><surname>Valenti</surname><given-names>A</given-names></name><name><surname>Visalli</surname><given-names>G</given-names></name><name><surname>Di Pietro</surname><given-names>A</given-names></name></person-group>. <article-title>Interleukin-6 signalling as a valuable cornerstone for molecular medicine</article-title> <comment>[Review]</comment>. <source>Int J Mol Med</source>. <year>2021</year>;<volume>47</volume>(<issue>6</issue>):<fpage>107</fpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2021.4940</pub-id><pub-id pub-id-type="pmid">33907833</pub-id></mixed-citation></ref>
<ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jawa</surname><given-names>RS</given-names></name><name><surname>Anillo</surname><given-names>S</given-names></name><name><surname>Huntoon</surname><given-names>K</given-names></name><name><surname>Baumann</surname><given-names>H</given-names></name><name><surname>Kulaylat</surname><given-names>M</given-names></name></person-group>. <article-title>Interleukin-6 in surgery, trauma, and critical care part II: clinical implications.</article-title> <source>J Intensive Care Med</source>. <year>2011</year>;<volume>26</volume>(<issue>2</issue>):<fpage>73</fpage>&#x2013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1177/0885066610384188</pub-id><pub-id pub-id-type="pmid">21464062</pub-id></mixed-citation></ref>
<ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alazawi</surname><given-names>W</given-names></name><name><surname>Pirmadjid</surname><given-names>N</given-names></name><name><surname>Lahiri</surname><given-names>R</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name></person-group>. <article-title>Inflammatory and immune responses to surgery and their clinical impact.</article-title> <source>Ann Surg</source>. <year>2016</year>;<volume>264</volume>(<issue>1</issue>):<fpage>73</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1097/SLA.0000000000001691</pub-id><pub-id pub-id-type="pmid">27275778</pub-id></mixed-citation></ref>
<ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>B</given-names></name><etal/></person-group> <article-title>Diagnostic and prognostic value of interleukin-6 in emergency department sepsis patients.</article-title> <source>Infect Drug Resist</source>. <year>2022</year>;<volume>15</volume>:<fpage>5557</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.2147/IDR.S384351</pub-id><pub-id pub-id-type="pmid">36172624</pub-id></mixed-citation></ref>
<ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choy</surname><given-names>EH</given-names></name><name><surname>De Benedetti</surname><given-names>F</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name><name><surname>Hashizume</surname><given-names>M</given-names></name><name><surname>John</surname><given-names>MR</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name></person-group>. <article-title>Translating IL-6 biology into effective treatments.</article-title> <source>Nat Rev Rheumatol</source>. <year>2020</year>;<volume>16</volume>(<issue>6</issue>):<fpage>335</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1038/s41584-020-0419-z</pub-id><pub-id pub-id-type="pmid">32327746</pub-id></mixed-citation></ref>
<ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Narazaki</surname><given-names>M</given-names></name><name><surname>Metwally</surname><given-names>H</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name></person-group>. <article-title>Historical overview of the interleukin-6 family cytokine.</article-title> <source>J Exp Med</source>. <year>2020</year>;<volume>217</volume>(<issue>5</issue>):<elocation-id>e20190347</elocation-id>. <pub-id pub-id-type="doi">10.1084/jem.20190347</pub-id><pub-id pub-id-type="pmid">32267936</pub-id></mixed-citation></ref>
<ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivas</surname><given-names>MC</given-names></name><name><surname>Villamarin Guerrero</surname><given-names>HF</given-names></name><name><surname>Tascon</surname><given-names>AJ</given-names></name><name><surname>Valderrama-Aguirre</surname><given-names>A</given-names></name></person-group>. <article-title>Plasma interleukin-6 levels correlate with survival in patients with bacterial sepsis and septic shock.</article-title> <source>Interv Med Appl Sci</source>. <year>2021</year>;<volume>11</volume>(<issue>4</issue>):<fpage>224</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1556/1646.2020.00006</pub-id><pub-id pub-id-type="pmid">36343289</pub-id></mixed-citation></ref>
<ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choy</surname><given-names>E</given-names></name><name><surname>Rose-John</surname><given-names>S</given-names></name></person-group>. <article-title>Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis.</article-title> <source>J Scleroderma Relat Disord</source>. <year>2017</year>;<volume>2</volume> <supplement>Suppl 2</supplement>:<fpage>S1</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.5301/jsrd.5000265</pub-id></mixed-citation></ref>
<ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Sturm</surname><given-names>R</given-names></name><name><surname>Henrich</surname><given-names>D</given-names></name><name><surname>Lupu</surname><given-names>L</given-names></name><name><surname>Rottluff</surname><given-names>K</given-names></name><name><surname>Marzi</surname><given-names>I</given-names></name><etal/></person-group> <article-title>Diagnostic and prognostic potential of exosomal cytokines IL-6 and IL-10 in polytrauma patients.</article-title> <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>(<issue>14</issue>):<fpage>11830</fpage>. <pub-id pub-id-type="doi">10.3390/ijms241411830</pub-id><pub-id pub-id-type="pmid">37511589</pub-id></mixed-citation></ref>
<ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rettig</surname><given-names>TC</given-names></name><name><surname>Verwijmeren</surname><given-names>L</given-names></name><name><surname>Dijkstra</surname><given-names>IM</given-names></name><name><surname>Boerma</surname><given-names>D</given-names></name><name><surname>van de Garde</surname><given-names>EM</given-names></name><name><surname>Noordzij</surname><given-names>PG</given-names></name></person-group>. <article-title>Postoperative interleukin-6 level and early detection of complications after elective major abdominal surgery.</article-title> <source>Ann Surg</source>. <year>2016</year>;<volume>263</volume>(<issue>6</issue>):<fpage>1207</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1097/SLA.0000000000001342</pub-id><pub-id pub-id-type="pmid">26135695</pub-id></mixed-citation></ref>
<ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>HG</given-names></name><name><surname>Tian</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>SY</given-names></name></person-group>. <article-title>Clinical utility of procalcitonin and its association with pathogenic microorganisms.</article-title> <source>Crit Rev Clin Lab Sci</source>. <year>2022</year>;<volume>59</volume>(<issue>2</issue>):<fpage>93</fpage>&#x2013;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1080/10408363.2021.1988047</pub-id><pub-id pub-id-type="pmid">34663176</pub-id></mixed-citation></ref>
<ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippi</surname><given-names>G</given-names></name></person-group>. <article-title>The origin of some laboratory medicine milestones.</article-title> <source>J Lab Precis Med</source>. <year>2019</year>;<volume>4</volume>:<fpage>14</fpage>. <pub-id pub-id-type="doi">10.21037/jlpm.2019.03.03</pub-id></mixed-citation></ref>
<ref id="r46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moya</surname><given-names>F</given-names></name><name><surname>Nieto</surname><given-names>A</given-names></name></person-group>. <article-title>R-Candela JL. Calcitonin biosynthesis: evidence for a precursor.</article-title> <source>Eur J Biochem</source>. <year>1975</year>;<volume>55</volume>(<issue>2</issue>):<fpage>407</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-1033.1975.tb02176.x</pub-id><pub-id pub-id-type="pmid">1201755</pub-id></mixed-citation></ref>
<ref id="r47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assicot</surname><given-names>M</given-names></name><name><surname>Gendrel</surname><given-names>D</given-names></name><name><surname>Carsin</surname><given-names>H</given-names></name><name><surname>Raymond</surname><given-names>J</given-names></name><name><surname>Guilbaud</surname><given-names>J</given-names></name><name><surname>Bohuon</surname><given-names>C</given-names></name></person-group>. <article-title>High serum procalcitonin concentrations in patients with sepsis and infection.</article-title> <source>Lancet</source>. <year>1993</year>;<volume>341</volume>(<issue>8844</issue>):<fpage>515</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/0140-6736(93)90277-N</pub-id><pub-id pub-id-type="pmid">8094770</pub-id></mixed-citation></ref>
<ref id="r48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vijayan</surname><given-names>AL</given-names></name></person-group>, Vanimaya, Ravindran S, Saikant R, Lakshmi S, Kartik R, et al. <article-title>Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy.</article-title> <source>J Intensive Care</source>. <year>2017</year>;<volume>5</volume>:<fpage>51</fpage>. <pub-id pub-id-type="doi">10.1186/s40560-017-0246-8</pub-id><pub-id pub-id-type="pmid">28794881</pub-id></mixed-citation></ref>
<ref id="r49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamade</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>DT</given-names></name></person-group>. <article-title>Procalcitonin: where are we now?</article-title> <source>Crit Care Clin</source>. <year>2020</year>;<volume>36</volume>(<issue>1</issue>):<fpage>23</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccc.2019.08.003</pub-id><pub-id pub-id-type="pmid">31733680</pub-id></mixed-citation></ref>
<ref id="r50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samsudin</surname><given-names>I</given-names></name><name><surname>Vasikaran</surname><given-names>SD</given-names></name></person-group>. <article-title>Clinical utility and measurement of procalcitonin.</article-title> <source>Clin Biochem Rev</source>. <year>2017</year>;<volume>38</volume>(<issue>2</issue>):<fpage>59</fpage>&#x2013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">29332972</pub-id></mixed-citation></ref>
<ref id="r51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuetz</surname><given-names>P</given-names></name><name><surname>Beishuizen</surname><given-names>A</given-names></name><name><surname>Broyles</surname><given-names>M</given-names></name><name><surname>Ferrer</surname><given-names>R</given-names></name><name><surname>Gavazzi</surname><given-names>G</given-names></name><name><surname>Gluck</surname><given-names>EH</given-names></name><etal/></person-group> <article-title>Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use.</article-title> <source>Clin Chem Lab Med</source>. <year>2019</year>;<volume>57</volume>(<issue>9</issue>):<fpage>1308</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1515/cclm-2018-1181</pub-id><pub-id pub-id-type="pmid">30721141</pub-id></mixed-citation></ref>
<ref id="r52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nargis</surname><given-names>W</given-names></name><name><surname>Ibrahim</surname><given-names>M</given-names></name><name><surname>Ahamed</surname><given-names>BU</given-names></name></person-group>. <article-title>Procalcitonin versus C-reactive protein: usefulness as biomarker of sepsis in ICU patient.</article-title> <source>Int J Crit Illn Inj Sci</source>. <year>2014</year>;<volume>4</volume>(<issue>3</issue>):<fpage>195</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4103/2229-5151.141356</pub-id><pub-id pub-id-type="pmid">25337480</pub-id></mixed-citation></ref>
<ref id="r53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kralovcova</surname><given-names>M</given-names></name><name><surname>M&#x00FC;ller</surname><given-names>J</given-names></name><name><surname>Hajsmanova</surname><given-names>Z</given-names></name><name><surname>Sigutova</surname><given-names>P</given-names></name><name><surname>Bultasova</surname><given-names>L</given-names></name><name><surname>Palatova</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Understanding the value of monocyte distribution width (MDW) in acutely ill medical patients presenting to the emergency department: a prospective single center evaluation.</article-title> <source>Sci Rep</source>. <year>2024</year>;<volume>14</volume>(<issue>1</issue>):<fpage>15255</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-024-65883-8</pub-id><pub-id pub-id-type="pmid">38956252</pub-id></mixed-citation></ref>
<ref id="r54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malinovska</surname><given-names>A</given-names></name><name><surname>Hernried</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Badaki-Makun</surname><given-names>O</given-names></name><name><surname>Fenstermacher</surname><given-names>K</given-names></name><name><surname>Ervin</surname><given-names>AM</given-names></name><etal/></person-group> <article-title>Monocyte distribution width as a diagnostic marker for infection: a systematic review and meta-analysis.</article-title> <source>Chest</source>. <year>2023</year>;<volume>164</volume>(<issue>1</issue>):<fpage>101</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2022.12.049</pub-id><pub-id pub-id-type="pmid">36681146</pub-id></mixed-citation></ref>
<ref id="r55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agnello</surname><given-names>L</given-names></name><name><surname>Lo Sasso</surname><given-names>B</given-names></name><name><surname>Bivona</surname><given-names>G</given-names></name><name><surname>Gambino</surname><given-names>CM</given-names></name><name><surname>Giglio</surname><given-names>RV</given-names></name><name><surname>Iacolino</surname><given-names>G</given-names></name><etal/></person-group> <article-title>Reference interval of monocyte distribution width (MDW) in healthy blood donors.</article-title> <source>Clin Chim Acta</source>. <year>2020</year>;<volume>510</volume>:<fpage>272</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2020.07.036</pub-id><pub-id pub-id-type="pmid">32710941</pub-id></mixed-citation></ref>
<ref id="r56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausfater</surname><given-names>P</given-names></name><name><surname>Robert Boter</surname><given-names>N</given-names></name><name><surname>Morales Indiano</surname><given-names>C</given-names></name><name><surname>Cancella de Abreu</surname><given-names>M</given-names></name><name><surname>Marin</surname><given-names>AM</given-names></name><name><surname>Pernet</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Monocyte distribution width (MDW) performance as an early sepsis indicator in the emergency department: comparison with CRP and procalcitonin in a multicenter international European prospective study.</article-title> <source>Crit Care</source>. <year>2021</year>;<volume>25</volume>(<issue>1</issue>):<fpage>227</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-021-03622-5</pub-id><pub-id pub-id-type="pmid">34193208</pub-id></mixed-citation></ref>
<ref id="r57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meraj</surname><given-names>F</given-names></name><name><surname>Shaikh</surname><given-names>S</given-names></name><name><surname>Maqsood</surname><given-names>S</given-names></name><name><surname>Kanani</surname><given-names>F</given-names></name><name><surname>Khan</surname><given-names>H</given-names></name><name><surname>Jamal</surname><given-names>S</given-names></name></person-group>. <article-title>Monocyte distribution width, a novel biomarker for early sepsis screening and comparison with procalcitonin and C-reactive protein.</article-title> <source>J Lab Physicians</source>. <year>2023</year>;<volume>15</volume>(<issue>2</issue>):<fpage>294</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1055/s-0042-1758666</pub-id><pub-id pub-id-type="pmid">37323592</pub-id></mixed-citation></ref>
<ref id="r58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Choi</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>SP</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>J</given-names></name></person-group>. <article-title>Monocyte distribution width (MDW) as a useful indicator for early screening of sepsis and discriminating false positive blood cultures.</article-title> <source>PLoS One</source>. <year>2022</year>;<volume>17</volume>(<issue>12</issue>):<elocation-id>e0279374</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0279374</pub-id><pub-id pub-id-type="pmid">36538555</pub-id></mixed-citation></ref>
<ref id="r59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Formenti</surname><given-names>P</given-names></name><name><surname>Gotti</surname><given-names>M</given-names></name><name><surname>Palmieri</surname><given-names>F</given-names></name><name><surname>Pastori</surname><given-names>S</given-names></name><name><surname>Roccaforte</surname><given-names>V</given-names></name><name><surname>Menozzi</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Presepsin in critical illness: current knowledge and future perspectives.</article-title> <source>Diagnostics (Basel)</source>. <year>2024</year>;<volume>14</volume>(<issue>12</issue>):<fpage>1311</fpage>. <pub-id pub-id-type="doi">10.3390/diagnostics14121311</pub-id><pub-id pub-id-type="pmid">38928726</pub-id></mixed-citation></ref>
<ref id="r60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaegashi</surname><given-names>Y</given-names></name><name><surname>Shirakawa</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Kojika</surname><given-names>M</given-names></name><name><surname>Imai</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis.</article-title> <source>J Infect Chemother</source>. <year>2005</year>;<volume>11</volume>(<issue>5</issue>):<fpage>234</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s10156-005-0400-4</pub-id><pub-id pub-id-type="pmid">16258819</pub-id></mixed-citation></ref>
<ref id="r61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galliera</surname><given-names>E</given-names></name><name><surname>Massaccesi</surname><given-names>L</given-names></name><name><surname>de Vecchi</surname><given-names>E</given-names></name><name><surname>Banfi</surname><given-names>G</given-names></name><name><surname>Romanelli</surname><given-names>MMC</given-names></name></person-group>. <article-title>Clinical application of presepsin as diagnostic biomarker of infection: overview and updates.</article-title> <source>Clin Chem Lab Med</source>. <year>2019</year>;<volume>58</volume>(<issue>1</issue>):<fpage>11</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1515/cclm-2019-0643</pub-id><pub-id pub-id-type="pmid">31421036</pub-id></mixed-citation></ref>
<ref id="r62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Q</given-names></name><name><surname>Wen</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>XC</given-names></name></person-group>. <article-title>Presepsin as a novel sepsis biomarker.</article-title> <source>World J Emerg Med</source>. <year>2014</year>;<volume>5</volume>(<issue>1</issue>):<fpage>16</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.5847/wjem.j.issn.1920-8642.2014.01.002</pub-id><pub-id pub-id-type="pmid">25215141</pub-id></mixed-citation></ref>
<ref id="r63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memar</surname><given-names>MY</given-names></name><name><surname>Baghi</surname><given-names>HB</given-names></name></person-group>. <article-title>Presepsin: a promising biomarker for the detection of bacterial infections.</article-title> <source>Biomed Pharmacother</source>. <year>2019</year>;<volume>111</volume>:<fpage>649</fpage>&#x2013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.12.124</pub-id><pub-id pub-id-type="pmid">30611989</pub-id></mixed-citation></ref>
<ref id="r64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>DW</given-names></name><name><surname>Seok</surname><given-names>H</given-names></name><name><surname>Ahn</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Diagnostic and prognostic value of presepsin and procalcitonin in non-infectious organ failure, sepsis, and septic shock: a prospective observational study according to the Sepsis-3 definitions.</article-title> <source>BMC Infect Dis</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>8</fpage>. <pub-id pub-id-type="doi">10.1186/s12879-021-07012-8</pub-id><pub-id pub-id-type="pmid">34983420</pub-id></mixed-citation></ref>
<ref id="r65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dr&#x0103;goescu</surname><given-names>AN</given-names></name><name><surname>P&#x0103;dureanu</surname><given-names>V</given-names></name><name><surname>St&#x0103;nculescu</surname><given-names>AD</given-names></name><name><surname>Chiu&#x021B;u</surname><given-names>LC</given-names></name><name><surname>Florescu</surname><given-names>DN</given-names></name><name><surname>Gheonea</surname><given-names>IA</given-names></name><etal/></person-group> <article-title>Presepsin as a potential prognostic marker for sepsis according to actual practice guidelines.</article-title> <source>J Pers Med</source>. <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>2</fpage>. <pub-id pub-id-type="doi">10.3390/jpm11010002</pub-id><pub-id pub-id-type="pmid">33374939</pub-id></mixed-citation></ref>
<ref id="r66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velissaris</surname><given-names>D</given-names></name><name><surname>Zareifopoulos</surname><given-names>N</given-names></name><name><surname>Karamouzos</surname><given-names>V</given-names></name><name><surname>Karanikolas</surname><given-names>E</given-names></name><name><surname>Pierrakos</surname><given-names>C</given-names></name><name><surname>Koniari</surname><given-names>I</given-names></name><etal/></person-group> <article-title>Presepsin as a diagnostic and prognostic biomarker in sepsis.</article-title> <source>Cureus</source>. <year>2021</year>;<volume>13</volume>(<issue>5</issue>):<elocation-id>e15019</elocation-id>. <pub-id pub-id-type="doi">10.7759/cureus.15019</pub-id><pub-id pub-id-type="pmid">34150378</pub-id></mixed-citation></ref>
<ref id="r67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Hond</surname><given-names>TAP</given-names></name><name><surname>Oosterheert</surname><given-names>JJ</given-names></name><name><surname>van Hemert-Glaubitz</surname><given-names>SJM</given-names></name><name><surname>Musson</surname><given-names>REA</given-names></name><name><surname>Kaasjager</surname><given-names>KAH</given-names></name></person-group>. <article-title>Pancreatic stone protein as a biomarker for sepsis at the emergency department of a large tertiary hospital.</article-title> <source>Pathogens</source>. <year>2022</year>;<volume>11</volume>(<issue>5</issue>):<fpage>559</fpage>. <pub-id pub-id-type="doi">10.3390/pathogens11050559</pub-id><pub-id pub-id-type="pmid">35631080</pub-id></mixed-citation></ref>
<ref id="r68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottari</surname><given-names>G</given-names></name><name><surname>Caruso</surname><given-names>M</given-names></name><name><surname>Paionni</surname><given-names>E</given-names></name><name><surname>De Luca</surname><given-names>M</given-names></name><name><surname>Romani</surname><given-names>L</given-names></name><name><surname>Pisani</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Accuracy of pancreatic stone protein for diagnosis of sepsis in children admitted to pediatric intensive care or high-dependency care: a pilot study.</article-title> <source>Ital J Pediatr</source>. <year>2023</year>;<volume>49</volume>(<issue>1</issue>):<fpage>134</fpage>. <pub-id pub-id-type="doi">10.1186/s13052-023-01540-6</pub-id><pub-id pub-id-type="pmid">37805604</pub-id></mixed-citation></ref>
<ref id="r69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname><given-names>F</given-names></name><name><surname>Eggimann</surname><given-names>P</given-names></name><name><surname>Daix</surname><given-names>T</given-names></name><name><surname>Fran&#x00E7;ois</surname><given-names>B</given-names></name><name><surname>Pugin</surname><given-names>J</given-names></name></person-group>. <article-title>Pancreatic stone protein measurement to screen and diagnose sepsis in the context of the surviving sepsis campaign recommendations.</article-title> <source>Med Res Arch</source>. <year>2023</year>;<volume>11</volume>(<issue>12</issue>):<fpage>1</fpage>&#x2013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.18103/mra.v11i12.4893</pub-id></mixed-citation></ref>
<ref id="r70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggimann</surname><given-names>P</given-names></name><name><surname>Que</surname><given-names>YA</given-names></name><name><surname>Rebeaud</surname><given-names>F</given-names></name></person-group>. <article-title>Measurement of pancreatic stone protein in the identification and management of sepsis.</article-title> <source>Biomark Med</source>. <year>2019</year>;<volume>13</volume>(<issue>2</issue>):<fpage>135</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.2217/bmm-2018-0194</pub-id><pub-id pub-id-type="pmid">30672312</pub-id></mixed-citation></ref>
<ref id="r71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>D</given-names></name><name><surname>Graf</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group>. <article-title>Elevated serum level of pancreatic stone protein/regenerating protein (PSP/reg) is observed in diabetic kidney disease.</article-title> <source>Oncotarget</source>. <year>2017</year>;<volume>8</volume>(<issue>24</issue>):<fpage>38145</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.16369</pub-id><pub-id pub-id-type="pmid">28418911</pub-id></mixed-citation></ref>
<ref id="r72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fidalgo</surname><given-names>P</given-names></name><name><surname>Nora</surname><given-names>D</given-names></name><name><surname>Coelho</surname><given-names>L</given-names></name><name><surname>Povoa</surname><given-names>P</given-names></name></person-group>. <article-title>Pancreatic stone protein: review of a new biomarker in sepsis.</article-title> <source>J Clin Med</source>. <year>2022</year>;<volume>11</volume>(<issue>4</issue>):<fpage>1085</fpage>. <pub-id pub-id-type="doi">10.3390/jcm11041085</pub-id><pub-id pub-id-type="pmid">35207355</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
